For help on how to get the results you want, see our search tips.
2 results
Medicine
Referrals Remove Referrals filter
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Medicine type
Exceptional circumstances Remove Exceptional circumstances filter
Additional monitoring Remove Additional monitoring filter
Conditional approval Remove Conditional approval filter
Referral safety status
Yes Remove Yes filter
Referral PRAC recommendation
Risk minimisation measures Remove Risk minimisation measures filter
Referral decision making model
PRAC-CHMP-EC Remove PRAC-CHMP-EC filter
-
List item
Referral: Janus kinase inhibitors (JAKi)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/01/2023, EC decision date: 10/03/2023, Last updated: 22/05/2023 -
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020